Atorvastatin Calcium
Product Images NDC 70934-615

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 70934-615). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (70934 615 30 Master Bottle Label Approval Rev A 04 20)

Label (70934 615 30 Master Bottle Label Approval   Rev A 04 20)
Arvastain Column Tatiets, USP 40 mg is a prescription drug with the NDC code 70934-615-30. It comes in the form of Calcium tablets and contains Atorvastatin USP 40 mg. Each bottle contains 30 tablets and is only available with a prescription. The manufacturer may be BRI based on the text provided.*
FDA Label Image

Atorvastatin-fig-1 (Atorvastatin Fig 1)

Atorvastatin-fig-1 (Atorvastatin Fig 1)
There is a graph representing the cumulative incidence of Atorvastatin and Placebo over 35 years, with a decrease in incidence for Atorvastatin when compared to Placebo. The graph also shows that Atorvastatin has a hazard ratio of 0.64 (p=0.0005).*
FDA Label Image

Atorvastatin-fig-2 (Atorvastatin Fig 2)

Atorvastatin-fig-2 (Atorvastatin Fig 2)
This text displays a chart or graph showing the cumulative hazard percentage over a 4-year follow-up period for a placebo group and a group treated with Atorvastatin. The graph indicates that Atorvastatin is associated with a lower risk of experiencing the primary endpoint compared to the placebo group.*
FDA Label Image

Atorvastatin-fig-3 (Atorvastatin Fig 3)

Atorvastatin-fig-3 (Atorvastatin Fig 3)
This text provides data on the percentage of subjects experiencing an event after taking different doses of atorvastatin for a certain period of time. The data shows that at a dose of 10 mg, no one experienced an event, while at a dose of 80 mg, the event rate was lowered by 22% compared to a placebo (P=0.0002). The chart shows the time to the first major cardiovascular endpoint in years.*
FDA Label Image

Atorvastatin-st (Atorvastatin St)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.